The new CPU with 96 beds for overnight stays, will conduct early-phase clinical pharmacology studies in normal healthy volunteers, special populations and patient populations over a spectrum of diseases.
The 60,000ft² facility will consist of pharmacy, processing labs and a patient recruitment staff for both the recruitment and screening of trial subjects.
The existing facility in Norwood will close at the conclusion of the move, according to the company.
Medpace president August Troendle said that the new facility is designed to conduct best in class Phase I studies doubling the company’s current capacity and investing in cutting edge instrumentation and process.
"The vision for a state of the art campus began in 2008 with the construction of the existing CRO and global headquarters building,"August added.
"By the end of 2012, we will see the completion of Medpace Reference Laboratories (MRL) and Medpace Bioanalytical Laboratories (MBL) facility at the new location.”